Pre-made Envafolimab benchmark antibody ( Single Domain Variable Fragment;H, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-188

Pre-made Envafolimab benchmark antibody (Single Domain Variable Fragment;H, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-188-1mg 1mg Inquiry
GMP-Bios-ab-188-10mg 10mg Inquiry
GMP-Bios-ab-188-100mg 100mg Inquiry
GMP-Bios-ab-188-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody
INN Name Envafolimab
FormatSingle Domain Variable Fragment;H
Species ReactivityHuman
CH1 IsotypeIgG1
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAlphamab;3D Medicines;Sun Yat-Sen University
Conditions Approvedna
Conditions ActiveBiliary cancer;Breast cancer;Solid tumours;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma
Conditions Discontinuedna
Development Techna